Company Performance Metrics
Mach One Corporation delivers biotechnology-based solutions to help address one of the world's most pressing and costly needs–positive, long-term health and longevity benefits for disease threatened animals of commercial operations. These problems cost production animal industries enormous amounts of money in both lower production levels and
attrition through loss of the animals themselves.
To help address health challenges faced in production animal industries, Mach One provides targeted, broad spectrum immunoglobulins (Iggs) that offer a new level of cost-effectiveness, improved health and ease of administration, with an initial focus on the beef and dairy industries.
There business model is highly symbiotic. It is based on solid collaboration with commercial dairies, farms, and ranches through our Bridge™ program. A program that provides the basis for support of other highly profitable opportunities in gamma globulin distribution and Nutraceutical production.
Whether it is the Igg production as a result of our patented plasma extraction from the host herd, or the future derivation of Nutraceutical component materials, Mach One's innovative business model is based on multiple applications for delivery of gamma globulins, the precursor materials that are derived from our manufacturing activity for the beef and dairy industry. Mach One intends to fully leverage the potential of its breakthrough solutions–eventually extending its product lines to include horses, swine, poultry, sheep, companion animals and ultimately human consumer applications.
